Data from the phase 3 LIBERTY-CUPID Study C evaluating the investigational use of Dupixent in biologic-naive patients with uncontrolled chronic ...

Sanofi is aiming to sign an agreement this weekend to sell control of its consumer health business to Clayton Dubilier & Rice ...

SALES FORECAST: The Paris-based group's sales are forecast at 12.63 billion euros, according to Visible Alpha. That compares with 11.96 billion euros for the same period the year before. As of ...

Sanofi will sell a 50% controlling stake in consumer healthcare unit Opella to private equity firm CD&R, with the French ...

French pharma major Sanofi has opened negotiations to sell a 50% controlling stake in its consumer health business Opella to ...

Under the proposed deal, the PE firm would take a controlling 50% stake in Sanofi’s Opella unit, with state-owned Bpifrance ...

US private equity firm CD&R has agreed to French government demands seeking to protect jobs and investment in France.

Thursday’s agreement with Orano Med is the second in as many months. Sanofi in September made its first foray into the ...

Paris: French drugmaker Sanofi's Monday confirmation that it plans to sell a controlling stake in its over-the-counter unit ...

The US Food and Drug Administration (FDA) has updated the US label for French pharma major Sanofi’s Flublok (Influenza ...

The transaction builds on a three-way partnership between Sanofi, Orano Med, and RadioMedix – signed in September with a €100 ...

Weeks after penning a $110 million upfront deal with Orano Med for the global rights to a neuroendocrine tumor treatment, ...